Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
WOCKHARDT ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
WOCKHARDT Mar-23 |
ACTAVIS Dec-18 |
WOCKHARDT/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 316 | 16,117 | - | |
Low | Rs | 145 | 10,811 | - | |
Sales per share (Unadj.) | Rs | 184.0 | 3,953.4 | - | |
Earnings per share (Unadj.) | Rs | -43.1 | -1,273.4 | - | |
Cash flow per share (Unadj.) | Rs | -25.7 | 416.6 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 231.7 | 16,305.9 | - | |
Shares outstanding (eoy) | m | 144.09 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.3 | 3.4 | 36.8% | |
Avg P/E ratio | x | -5.3 | -10.6 | 50.6% | |
P/CF ratio (eoy) | x | -9.0 | 32.3 | -27.8% | |
Price / Book Value ratio | x | 1.0 | 0.8 | 120.5% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 33,202 | 4,478,069 | 0.7% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 6,370 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 77,804.7 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,060.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 26,510 | 1,314,899 | 2.0% | |
Other income | Rs m | 1,220 | 25,145 | 4.9% | |
Total revenues | Rs m | 27,730 | 1,340,044 | 2.1% | |
Gross profit | Rs m | -1,930 | 34,457 | -5.6% | |
Depreciation | Rs m | 2,510 | 562,091 | 0.4% | |
Interest | Rs m | 3,020 | 75,877 | 4.0% | |
Profit before tax | Rs m | -6,240 | -578,366 | 1.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,507 | 0.0% | |
Tax | Rs m | -30 | -7,330 | 0.4% | |
Profit after tax | Rs m | -6,210 | -423,530 | 1.5% | |
Gross profit margin | % | -7.3 | 2.6 | -277.8% | |
Effective tax rate | % | 0.5 | 1.3 | 37.9% | |
Net profit margin | % | -23.4 | -32.2 | 72.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 19,140 | 539,303 | 3.5% | |
Current liabilities | Rs m | 34,350 | 477,085 | 7.2% | |
Net working cap to sales | % | -57.4 | 4.7 | -1,212.5% | |
Current ratio | x | 0.6 | 1.1 | 49.3% | |
Inventory Days | Days | 39 | 20 | 201.1% | |
Debtors Days | Days | 11 | 66 | 16.5% | |
Net fixed assets | Rs m | 48,670 | 148,839 | 32.7% | |
Share capital | Rs m | 720 | 0 | - | |
Net worth | Rs m | 33,380 | 5,423,345 | 0.6% | |
Long term debt | Rs m | 2,240 | 1,909,756 | 0.1% | |
Total assets | Rs m | 70,750 | 8,477,923 | 0.8% | |
Interest coverage | x | -1.1 | -6.6 | 16.1% | |
Debt to equity ratio | x | 0.1 | 0.4 | 19.1% | |
Sales to assets ratio | x | 0.4 | 0.2 | 241.6% | |
Return on assets | % | -4.5 | -4.1 | 110.0% | |
Return on equity | % | -18.6 | -7.8 | 238.2% | |
Return on capital | % | -9.0 | -4.8 | 186.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,530 | 469,764 | 0.3% | |
From Investments | Rs m | -1,250 | 258,074 | -0.5% | |
From Financial Activity | Rs m | -3,150 | -806,256 | 0.4% | |
Net Cashflow | Rs m | -2,800 | -78,026 | 3.6% |
Compare WOCKHARDT With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Compare WOCKHARDT With: PHARMAIDS PH KIMIA BIOSCIENCES EMMESSAR CHM MESCO PHARMA TYCHE INDUSTRIES
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.